GlaxoSmithKline "in-line," estimates revised

02/24/06 - Goldman Sachs

LONDON, February 24 (newratings.com) - Analysts at Goldman Sachs maintain their "in-line" rating on GlaxoSmithKline (GSK-GBX), while revising their estimates for the company.

In a research note published this morning, the analysts mention that the US FDA has approved the generic version of the company's Flonase, a fluticasone nasal spray for rhinitis/allergy. More generic competition is expected for GlaxoSmithKline's Flonase, the analysts say. The EPS estimate for 2006 has been reduced from 93.7p to 90.7p. The EPS estimate for 2007 has been raised from 102.4p to 103.1p.